Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes.

Journal Article (Journal Article)

The safety and efficacy of anti-diabetic drugs are critical for maximizing the beneficial impacts of well-controlled blood glucose on the prognosis of individuals with COVID-19 and pre-existing type 2 diabetes (T2D). Metformin is the most commonly prescribed first-line medication for T2D, but its impact on the outcomes of individuals with COVID-19 and T2D remains to be clarified. Our current retrospective study in a cohort of 1,213 hospitalized individuals with COVID-19 and pre-existing T2D indicated that metformin use was significantly associated with a higher incidence of acidosis, particularly in cases with severe COVID-19, but not with 28-day COVID-19-related mortality. Furthermore, metformin use was significantly associated with reduced heart failure and inflammation. Our findings provide clinical evidence in support of continuing metformin treatment in individuals with COVID-19 and pre-existing T2D, but acidosis and kidney function should be carefully monitored in individuals with severe COVID-19.

Full Text

Duke Authors

Cited Authors

  • Cheng, X; Liu, Y-M; Li, H; Zhang, X; Lei, F; Qin, J-J; Chen, Z; Deng, K-Q; Lin, L; Chen, M-M; Song, X; Xia, M; Huang, X; Liu, W; Cai, J; Zhang, X-J; Zhou, F; Zhang, P; Wang, Y; Ma, X; Xu, Q; Yang, J; Ye, P; Mao, W; Huang, X; Xia, J; Zhang, B-H; Guo, J; Zhu, L; Lu, Z; Yuan, Y; Wei, X; She, Z-G; Ji, Y-X; Li, H

Published Date

  • October 6, 2020

Published In

Volume / Issue

  • 32 / 4

Start / End Page

  • 537 - 547.e3

PubMed ID

  • 32861268

Pubmed Central ID

  • PMC7439986

Electronic International Standard Serial Number (EISSN)

  • 1932-7420

Digital Object Identifier (DOI)

  • 10.1016/j.cmet.2020.08.013


  • eng

Conference Location

  • United States